1
|
Kelemen ÁA, Satala G, Bojarski AJ, Keserű GM. Spiro[pyrrolidine-3,3'-oxindoles] and Their Indoline Analogues as New 5-HT6 Receptor Chemotypes. Molecules 2017; 22:molecules22122221. [PMID: 29240714 PMCID: PMC6149751 DOI: 10.3390/molecules22122221] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Revised: 12/11/2017] [Accepted: 12/12/2017] [Indexed: 11/18/2022] Open
Abstract
Synthetic derivatives of spiro[pyrrolidinyl-3,3′-oxindole] alkaloids (coerulescine analogues) were investigated as new ligands for aminergic G-protein coupled receptors (GPCRs). The chemical starting point 2′-phenylspiro[indoline-3,3′-pyrrolidin]-2-one scaffold was identified by virtual fragment screening utilizing ligand- and structure based methods. As a part of the hit-to-lead optimization a structure-activity relationship analysis was performed to explore the differently substituted 2′-phenyl-derivatives, introducing the phenylsulphonyl pharmacophore and examining the corresponding reduced spiro[pyrrolidine-3,3′-indoline] scaffold. The optimization process led to ligands with submicromolar affinities towards the 5-HT6 receptor that might serve as viable leads for further optimization.
Collapse
Affiliation(s)
- Ádám A Kelemen
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok körútja 2, H1117 Budapest, Hungary.
| | - Grzegorz Satala
- Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Krakow, Poland.
| | - Andrzej J Bojarski
- Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343 Krakow, Poland.
| | - György M Keserű
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok körútja 2, H1117 Budapest, Hungary.
| |
Collapse
|
2
|
de Jong IE, Mørk A. Antagonism of the 5-HT 6 receptor – Preclinical rationale for the treatment of Alzheimer's disease. Neuropharmacology 2017; 125:50-63. [DOI: 10.1016/j.neuropharm.2017.07.010] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Revised: 06/30/2017] [Accepted: 07/11/2017] [Indexed: 11/29/2022]
|
3
|
Dobi K, Flachner B, Pukáncsik M, Máthé E, Bognár M, Szaszkó M, Magyar C, Hajdú I, Lőrincz Z, Simon I, Fülöp F, Cseh S, Dormán G. Combination of Pharmacophore Matching, 2D Similarity Search, andIn VitroBiological Assays in the Selection of Potential 5-HT6Antagonists from Large Commercial Repositories. Chem Biol Drug Des 2015; 86:864-80. [DOI: 10.1111/cbdd.12563] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Revised: 02/06/2015] [Accepted: 03/10/2015] [Indexed: 12/13/2022]
Affiliation(s)
| | | | | | - Enikő Máthé
- Targetex Kft.; Kápolna köz 4/a Dunakeszi H-2120 Hungary
| | | | - Mária Szaszkó
- Targetex Kft.; Kápolna köz 4/a Dunakeszi H-2120 Hungary
| | - Csaba Magyar
- Institute of Enzymology; Research Centre for Natural Sciences; Hungarian Academy of Sciences; Magyar Tudósok körútja 2. Budapest H-1117 Hungary
| | - István Hajdú
- Targetex Kft.; Kápolna köz 4/a Dunakeszi H-2120 Hungary
- Institute of Enzymology; Research Centre for Natural Sciences; Hungarian Academy of Sciences; Magyar Tudósok körútja 2. Budapest H-1117 Hungary
| | - Zsolt Lőrincz
- Targetex Kft.; Kápolna köz 4/a Dunakeszi H-2120 Hungary
| | - István Simon
- Institute of Enzymology; Research Centre for Natural Sciences; Hungarian Academy of Sciences; Magyar Tudósok körútja 2. Budapest H-1117 Hungary
| | - Ferenc Fülöp
- Institute of Pharmaceutical Chemistry; University of Szeged; Eötvös u. 6. Szeged H-6720 Hungary
| | - Sándor Cseh
- Targetex Kft.; Kápolna köz 4/a Dunakeszi H-2120 Hungary
| | - György Dormán
- Targetex Kft.; Kápolna köz 4/a Dunakeszi H-2120 Hungary
| |
Collapse
|
4
|
Nirogi RVS, Bandyala TR, Reballi V, Konda JB, Daulatabad AV, Khagga M. Design, synthesis and pharmacological evaluation of indolylsulfonamide amines as potent and selective 5-HT6 receptor antagonists. J Enzyme Inhib Med Chem 2014; 30:85-97. [PMID: 24666297 DOI: 10.3109/14756366.2014.889126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
A series of N'-[3-(indole-1-sulfonyl) aryl]-N,N-dimethyl ethane-1,2-diamines and N'-[3-(indole-1-sulfonyl) aryl]-N,N-dimethyl propane-1,3-diamines was designed and synthesized as 5-HT6 receptor ligands. These compounds, when screened in a functional reporter gene-based assay, displayed potent antagonistic activity with Kb values in the range of 1.8-60 nM. The lead compound 9y has shown good ADME surrogate properties, acceptable pharmacokinetic profile and is active in animal models of cognition like novel object recognition test and Morris water maze. It was selected for detailed profiling.
Collapse
Affiliation(s)
- Ramakrishna V S Nirogi
- Discovery Research-Medicinal Chemistry, Suven Life Sciences Limited, Serene Chambers , Banjara Hills, Hyderabad , India and
| | | | | | | | | | | |
Collapse
|
5
|
Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011; 95:163-212. [PMID: 21878363 DOI: 10.1016/j.pneurobio.2011.08.004] [Citation(s) in RCA: 135] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2011] [Revised: 08/05/2011] [Accepted: 08/15/2011] [Indexed: 01/23/2023]
Abstract
Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline in dopamine levels in the striatum, a breadth of non-motor features and treatment-related complications in which the serotonergic system plays a pivotal role are increasingly recognised. Serotonin (5-HT)-mediated neurotransmission is altered in PD and the roles of the different 5-HT receptor subtypes in disease manifestations have been investigated. The aims of this article are to summarise and discuss all published preclinical and clinical studies that have investigated the serotonergic system in PD and related animal models, in order to recapitulate the state of the current knowledge and to identify areas that need further research and understanding.
Collapse
Affiliation(s)
- Philippe Huot
- Toronto Western Research Institute, MCL 11-419, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8
| | | | | |
Collapse
|
6
|
Ivachtchenko AV, Ivanenkov YA, Tkachenko SE. 5-hydroxytryptamine subtype 6 receptor modulators: a patent survey. Expert Opin Ther Pat 2010; 20:1171-96. [DOI: 10.1517/13543776.2010.494661] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
7
|
Sharma BK, Singh P, Sarbhai K, Prabhakar YS. A quantitative structure-activity relationship study on serotonin 5-HT6) receptor ligands: indolyl and piperidinyl sulphonamides. SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2010; 21:369-388. [PMID: 20544556 DOI: 10.1080/10629361003773997] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The serotonin 5-HT(6) binding affinity of indolyl- and piperidinyl-sulphonamide derivatives has been analysed with topological and molecular features with DRAGON software. Analysis of the structural features in conjunction with the biological endpoints in combinatorial protocol in multiple linear regression (CP-MLR) led to the identification of 25 descriptors for modelling the activity. The study clearly suggested the role of an average Randic-type eigenvector-based index from adjacency matrix, VRA2, number of secondary aliphatic amines, nNHR, the sum of the topological distance between N and O, T(N...O), ring tertiary carbon atoms, nCrHR, and CH2RX type fragment, C-006, in a molecular structure to optimize the 5-HT(6) binding affinities of titled compounds. The PLS analysis confirmed the dominance of information content of CP-MLR identified descriptors for modelling the activity when compared with those of leftover ones.
Collapse
Affiliation(s)
- B K Sharma
- Department of Chemistry, S.K. Government College, Sikar-332 001, India.
| | | | | | | |
Collapse
|
8
|
Liu KG, Robichaud AJ. 5-HT6antagonists as potential treatment for cognitive dysfunction. Drug Dev Res 2009. [DOI: 10.1002/ddr.20293] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
9
|
Shadrina M, Nikopensius T, Slominsky P, Illarioshkin S, Bagyeva G, Markova E, Ivanova-Smolenskaia I, Kurg A, Limborska S, Metspalu A. Association study of sporadic Parkinson's disease genetic risk factors in patients from Russia by APEX technology. Neurosci Lett 2006; 405:212-6. [PMID: 16876316 DOI: 10.1016/j.neulet.2006.06.066] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2006] [Revised: 06/14/2006] [Accepted: 06/30/2006] [Indexed: 11/15/2022]
Abstract
Most patients with Parkinson's disease (PD) have sporadic form of the disease with a multifactorial etiology due to interactions between environmental conditions and the genetic constitution of the individuals. We have analyzed by APEX technology 50 single nucleotide polymorphisms (SNPs) in 19 genes related to cholecystokinin, serotonin, dopamine and opioid neurotransmission. Significant differences in the allele and genotype frequencies between the controls and PD patients were detected for four SNPs from three genes (serotonin 2A receptor (rs6311, P=0.043), Wolfram syndrome 1 (rs1801211, P=0.007), proopiomelanocortin (rs28930368, P=0.026 and rs2071345, P=0.027) genes). Two SNPs in proopiomelanocortin (POMC) gene were also associated with different clinical forms of PD. Our data suggest that at least three genes involved in neurotransmitter systems may have more specific role in genetic predisposition to PD.
Collapse
Affiliation(s)
- Maria Shadrina
- Institute of Molecular Genetics, Russian Academy of Sciences, Kurchatov sq. 2, Moscow 123 182, Russia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 2005; 108:320-33. [PMID: 16005519 DOI: 10.1016/j.pharmthera.2005.05.001] [Citation(s) in RCA: 183] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2005] [Accepted: 05/04/2005] [Indexed: 11/28/2022]
Abstract
Over the past decade, there has been increasing interest in the role of serotonin 6 (5-HT6) receptors in higher cognitive processes such as memory. Polymorphisms of the 5-HT6 receptor have been implicated in syndromes that affect cognition, such as schizophrenia and dementia. Manipulation of 5-HT6 receptor activity alters the transmission of several neurotransmitters important in memory: acetylcholine and glutamate, as well as dopamine, ã-aminobutyric acid (GABA), epinephrine (E), and norepinephrine (NE). Several 5-HT6 antagonists have been developed, advancing the understanding of the relationship between 5-HT6 blockade and memory consolidation in diverse learning paradigms. There is also evidence that 5-HT6 receptor activity affects anxiety behaviors and may be involved in the pathophysiology of schizophrenia. Several clinically useful atypical antipsychotics and antidepressants have 5-HT6 affinity, but recently developed selective 5-HT6 receptor antagonists may present attractive, new therapeutic options for several types of disease states.
Collapse
Affiliation(s)
- Ellen S Mitchell
- University of Washington, Box 359911, Harborview Medical Center, 325 9th Avenue, Seattle, WA 98104, USA
| | | |
Collapse
|
11
|
Lotrich FE, Pollock BG. Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatr Dis Treat 2005; 1:17-35. [PMID: 18568127 PMCID: PMC2426818 DOI: 10.2147/nedt.1.1.17.52301] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Selective serotonin reuptake inhibitors (SSRIs) can safely and successfully treat major depression, although a substantial number of patients benefit only partially or not at all from treatment. Genetic polymorphisms may play a major role in determining the response to SSRI treatment. Nonetheless, it is likely that efficacy is determined by multiple genes, with individual genetic polymorphisms having a limited effect size. Initial studies have identified the promoter polymorphism in the gene coding for the serotonin reuptake transporter as moderating efficacy for several SSRIs. The goal of this review is to suggest additional plausible polymorphisms that may be involved in antidepressant efficacy. These include genes affecting intracellular transductional cascades; neuronal growth factors; stress-related hormones, such as corticotropin-releasing hormone and glucocorticoid receptors; ion channels and synaptic efficacy; and adaptations of monoaminergic pathways. Association analyses to examine these candidate genes may facilitate identification of patients for targeted alternative therapies. Determining which genes are involved may also assist in identifying future, novel treatments.
Collapse
Affiliation(s)
- Francis E Lotrich
- University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Department of Psychiatry Pittsburgh, PA, USA.
| | | |
Collapse
|
12
|
Tzenova J, Kaplan BJ, Petryshen TL, Field LL. Confirmation of a dyslexia susceptibility locus on chromosome 1p34-p36 in a set of 100 Canadian families. Am J Med Genet B Neuropsychiatr Genet 2004; 127B:117-24. [PMID: 15108193 DOI: 10.1002/ajmg.b.20139] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Dyslexia is a common and genetically complex trait that manifests primarily as a reading disability independent of general intelligence and educational opportunity. Strong evidence for a dyslexia susceptibility locus on chromosome 1p34-p36 (near marker D1S199) was recently reported, and an earlier study found suggestive evidence for linkage to the same region. We tested for the presence of a dyslexia gene in this region in a sample of 100 Canadian families using both qualitative and quantitative definitions of the phenotype. Using a qualitative definition of dyslexia (affected, unaffected, or uncertain), the largest multipoint Genehunter Maximum LOD-Score (MLS) in 100 core nuclear families was 3.65 at D1S507, distal to D1S199. Quantitative trait locus (QTL) linkage analysis was performed for four measures of dyslexia (phonological awareness, phonological coding, spelling, and rapid automatized naming speed) employing the variance components approach implemented in Genehunter. Using a model with QTL additive and dominance variance and polygenic additive variance, the multipoint LOD scores maximized proximal to D1S199 (between D1S552 and D1S1622), with peaks of 4.01 for spelling and 1.65 for phonological coding (corresponding LOD scores under 1 degree of freedom were 3.30 and 1.13, respectively). In conclusion, our study confirms and strengthens recent findings of a dyslexia susceptibility gene on chromosome 1p34-p36 (now designated DYX8).
Collapse
Affiliation(s)
- Jordana Tzenova
- Department of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | | | | | | |
Collapse
|
13
|
Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 2002; 9 Suppl 3:1-6. [PMID: 12464115 DOI: 10.1046/j.1468-1331.9.s3.1.x] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
While Parkinson's disease is undoubtedly a disorder with a primary pathology of dopamine neuronal loss, that loss of dopamine and subsequent dopamine replacement therapy leads to imbalances in many non-dopaminergic transmitter systems, including 5-hydroxytryptamine (5-HT). Recent advances in understanding the role of 5-HT in parkinsonism and the generation of side-effects of dopamine replacement therapy (e.g. wearing-off and levodopa-induced dyskinesia) have identified 5-HT1A, 5-HT1B and 5-HT2C receptors as potential therapeutic targets in Parkinson's disease.
Collapse
MESH Headings
- Animals
- Antiparkinson Agents/adverse effects
- Antiparkinson Agents/therapeutic use
- Basal Ganglia/metabolism
- Basal Ganglia/physiology
- Drug Delivery Systems
- Drug Tolerance
- Dyskinesia, Drug-Induced/etiology
- Dyskinesia, Drug-Induced/prevention & control
- Humans
- Levodopa/adverse effects
- Levodopa/therapeutic use
- Neural Pathways
- Parkinson Disease/drug therapy
- Parkinson Disease/metabolism
- Receptor, Serotonin, 5-HT1B
- Receptor, Serotonin, 5-HT2C
- Receptors, Serotonin/drug effects
- Receptors, Serotonin/physiology
- Receptors, Serotonin, 5-HT1
- Serotonin/metabolism
- Serotonin Agents/therapeutic use
Collapse
Affiliation(s)
- S L Nicholson
- University of Manchester, School of Biological Sciences, UK
| | | |
Collapse
|